Skip to main content
Top
Published in: Molecular Neurodegeneration 1/2014

Open Access 01-12-2014 | Research article

Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5 – implications for dementia with Lewy bodies

Authors: Cassia R Overk, Anna Cartier, Gideon Shaked, Edward Rockenstein, Kiren Ubhi, Brian Spencer, Diana L Price, Christina Patrick, Paula Desplats, Eliezer Masliah

Published in: Molecular Neurodegeneration | Issue 1/2014

Login to get access

Abstract

Background

In dementia with Lewy bodies (DLB) abnormal interactions between α-synuclein (α-syn) and beta amyloid (Aβ) result in selective degeneration of neurons in the neocortex, limbic system and striatum. However, factors rendering these neurons selectively vulnerable have not been fully investigated. The metabotropic glutamate receptor 5 (mGluR5) has been shown to be up regulated in DLB and might play a role as a mediator of the neurotoxic effects of Aβ and α-syn in vulnerable neuronal populations. In this context, the main objective of the present study was to investigate the role of mGluR5 as a mediator of the neurotoxic effects of α-syn and Aβ in the hippocampus.

Results

We generated double transgenic mice over-expressing amyloid precursor protein (APP) and α-syn under the mThy1 cassette and investigated the relationship between α-syn cleavage, Aβ, mGluR5 and neurodegeneration in the hippocampus. We found that compared to the single tg mice, the α-syn/APP tg mice displayed greater accumulation of α-syn and mGluR5 in the CA3 region of the hippocampus compared to the CA1 and other regions. This was accompanied by loss of CA3 (but not CA1) neurons in the single and α-syn/APP tg mice and greater loss of MAP 2 and synaptophysin in the CA3 in the α-syn/APP tg. mGluR5 gene transfer using a lentiviral vector into the hippocampus CA1 region resulted in greater α-syn accumulation and neurodegeneration in the single and α-syn/APP tg mice. In contrast, silencing mGluR5 with a lenti-shRNA protected neurons in the CA3 region of tg mice. In vitro, greater toxicity was observed in primary hippocampal neuronal cultures treated with Aβ oligomers and over-expressing α-syn; this effect was attenuated by down-regulating mGluR5 with an shRNA lentiviral vector. In α-syn-expressing neuronal cells lines, Aβ oligomers promoted increased intracellular calcium levels, calpain activation and α-syn cleavage resulting in caspase-3-dependent cell death. Treatment with pharmacological mGluR5 inhibitors such as 2-Methyl-6-(phenylethynyl)pyridine (MPEP) and 3-((2-Methyl-4-thiazolyl)ethynyl)pyridine (MTEP) attenuated the toxic effects of Aβ in α-syn-expressing neuronal cells.

Conclusions

Together, these results support the possibility that vulnerability of hippocampal neurons to α-syn and Aβ might be mediated via mGluR5. Moreover, therapeutical interventions targeting mGluR5 might have a role in DLB.
Appendix
Available only for authorised users
Literature
1.
go back to reference As A: Alzheimer’s disease facts and figures. Alzheimer’s Dementia. 2013, 2013 (9): 1-71. As A: Alzheimer’s disease facts and figures. Alzheimer’s Dementia. 2013, 2013 (9): 1-71.
2.
go back to reference Masters CL, Selkoe DJ: Biochemistry of amyloid beta-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med. 2012, 2: a006262-PubMedCentralCrossRefPubMed Masters CL, Selkoe DJ: Biochemistry of amyloid beta-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med. 2012, 2: a006262-PubMedCentralCrossRefPubMed
4.
go back to reference Trojanowski J, Goedert M, Iwatsubo T, Lee V: Fatal attractions: abnormal protein aggregation and neuron death in Parkinson’s disease and lewy body dementia. Cell Death Differ. 1998, 5: 832-837. 10.1038/sj.cdd.4400432.CrossRefPubMed Trojanowski J, Goedert M, Iwatsubo T, Lee V: Fatal attractions: abnormal protein aggregation and neuron death in Parkinson’s disease and lewy body dementia. Cell Death Differ. 1998, 5: 832-837. 10.1038/sj.cdd.4400432.CrossRefPubMed
5.
go back to reference Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M: Alpha-synuclein in Lewy bodies. Nature. 1997, 388: 839-840. 10.1038/42166.CrossRefPubMed Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M: Alpha-synuclein in Lewy bodies. Nature. 1997, 388: 839-840. 10.1038/42166.CrossRefPubMed
6.
go back to reference Hashimoto M, Hernandez-Ruiz S, Hsu L, Sisk A, Xia Y, Takeda A, Sundsmo M, Masliah E: Human recombinant NACP/a-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res. 1998, 799: 301-306. 10.1016/S0006-8993(98)00514-9.CrossRefPubMed Hashimoto M, Hernandez-Ruiz S, Hsu L, Sisk A, Xia Y, Takeda A, Sundsmo M, Masliah E: Human recombinant NACP/a-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res. 1998, 799: 301-306. 10.1016/S0006-8993(98)00514-9.CrossRefPubMed
7.
go back to reference Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, Brooks DJ, Dickson DW, Dubois B, Emre M, Fahn S, Farmer JM, Galasko D, Galvin JE, Goetz CG, Growdon JH, Gwinn-Hardy KA, Hardy J, Heutink P, Iwatsubo T, Kosaka K, Lee VM, Leverenz JB, Masliah E, McKeith IG, Nussbaum RL, Olanow CW, Ravina BM, Singleton AB, Tanner CM, et al: DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007, 68: 812-819. 10.1212/01.wnl.0000256715.13907.d3.CrossRefPubMed Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, Brooks DJ, Dickson DW, Dubois B, Emre M, Fahn S, Farmer JM, Galasko D, Galvin JE, Goetz CG, Growdon JH, Gwinn-Hardy KA, Hardy J, Heutink P, Iwatsubo T, Kosaka K, Lee VM, Leverenz JB, Masliah E, McKeith IG, Nussbaum RL, Olanow CW, Ravina BM, Singleton AB, Tanner CM, et al: DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007, 68: 812-819. 10.1212/01.wnl.0000256715.13907.d3.CrossRefPubMed
8.
go back to reference McKeith IG: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis. 2006, 9: 417-423.PubMed McKeith IG: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis. 2006, 9: 417-423.PubMed
9.
go back to reference Pletnikova O, West N, Lee MK, Rudow GL, Skolasky RL, Dawson TM, Marsh L, Troncoso JC: Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging. 2005, 26: 1183-1192. 10.1016/j.neurobiolaging.2004.10.006.CrossRefPubMed Pletnikova O, West N, Lee MK, Rudow GL, Skolasky RL, Dawson TM, Marsh L, Troncoso JC: Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging. 2005, 26: 1183-1192. 10.1016/j.neurobiolaging.2004.10.006.CrossRefPubMed
10.
go back to reference Lippa CF, Fujiwara H, Mann DM, Giasson B, Baba M, Schmidt ML, Nee LE, O’Connell B, Pollen DA, St George-Hyslop P, Ghetti B, Nochlin D, Bird TD, Cairns NJ, Lee VM, Iwatsubo T, Trojanowski JQ: Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer’s disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol. 1998, 153: 1365-1370. 10.1016/S0002-9440(10)65722-7.PubMedCentralCrossRefPubMed Lippa CF, Fujiwara H, Mann DM, Giasson B, Baba M, Schmidt ML, Nee LE, O’Connell B, Pollen DA, St George-Hyslop P, Ghetti B, Nochlin D, Bird TD, Cairns NJ, Lee VM, Iwatsubo T, Trojanowski JQ: Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer’s disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol. 1998, 153: 1365-1370. 10.1016/S0002-9440(10)65722-7.PubMedCentralCrossRefPubMed
11.
go back to reference Morales R, Moreno-Gonzalez I, Soto C: Cross-seeding of misfolded proteins: implications for etiology and pathogenesis of protein misfolding diseases. PLoS Pathog. 2013, 9: e1003537-10.1371/journal.ppat.1003537.PubMedCentralCrossRefPubMed Morales R, Moreno-Gonzalez I, Soto C: Cross-seeding of misfolded proteins: implications for etiology and pathogenesis of protein misfolding diseases. PLoS Pathog. 2013, 9: e1003537-10.1371/journal.ppat.1003537.PubMedCentralCrossRefPubMed
12.
go back to reference Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L: beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer’s disease and Parkinson’s disease. Proc Natl Acad Sci U S A. 2001, 98: 12245-12250. 10.1073/pnas.211412398.PubMedCentralCrossRefPubMed Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L: beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer’s disease and Parkinson’s disease. Proc Natl Acad Sci U S A. 2001, 98: 12245-12250. 10.1073/pnas.211412398.PubMedCentralCrossRefPubMed
13.
go back to reference Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, Mizuno H, Spencer B, Rockenstein E, Trejo M, Platoshyn O, Yuan JX, Masliah E: Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer’s and Parkinson’s diseases. PLoS One. 2008, 3: e3135-10.1371/journal.pone.0003135.PubMedCentralCrossRefPubMed Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, Mizuno H, Spencer B, Rockenstein E, Trejo M, Platoshyn O, Yuan JX, Masliah E: Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer’s and Parkinson’s diseases. PLoS One. 2008, 3: e3135-10.1371/journal.pone.0003135.PubMedCentralCrossRefPubMed
14.
go back to reference Mandal PK, Pettegrew JW, Masliah E, Hamilton RL, Mandal R: Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer’s and Parkinson’s in dementia with Lewy body disease. Neurochem Res. 2006, 31: 1153-1162. 10.1007/s11064-006-9140-9.CrossRefPubMed Mandal PK, Pettegrew JW, Masliah E, Hamilton RL, Mandal R: Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer’s and Parkinson’s in dementia with Lewy body disease. Neurochem Res. 2006, 31: 1153-1162. 10.1007/s11064-006-9140-9.CrossRefPubMed
15.
go back to reference Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM: Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci. 2010, 30: 7281-7289. 10.1523/JNEUROSCI.0490-10.2010.PubMedCentralCrossRefPubMed Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM: Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci. 2010, 30: 7281-7289. 10.1523/JNEUROSCI.0490-10.2010.PubMedCentralCrossRefPubMed
16.
go back to reference Hamilton RL: Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 2000, 10: 378-384.CrossRefPubMed Hamilton RL: Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 2000, 10: 378-384.CrossRefPubMed
17.
go back to reference Zaja-Milatovic S, Keene CD, Montine KS, Leverenz JB, Tsuang D, Montine TJ: Selective dendritic degeneration of medium spiny neurons in dementia with Lewy bodies. Neurology. 2006, 66: 1591-1593. 10.1212/01.wnl.0000216137.09685.c1.CrossRefPubMed Zaja-Milatovic S, Keene CD, Montine KS, Leverenz JB, Tsuang D, Montine TJ: Selective dendritic degeneration of medium spiny neurons in dementia with Lewy bodies. Neurology. 2006, 66: 1591-1593. 10.1212/01.wnl.0000216137.09685.c1.CrossRefPubMed
18.
go back to reference Harding AJ, Lakay B, Halliday GM: Selective hippocampal neuron loss in dementia with Lewy bodies. Ann Neurol. 2002, 51: 125-128. 10.1002/ana.10071.CrossRefPubMed Harding AJ, Lakay B, Halliday GM: Selective hippocampal neuron loss in dementia with Lewy bodies. Ann Neurol. 2002, 51: 125-128. 10.1002/ana.10071.CrossRefPubMed
19.
go back to reference Price DL, Rockenstein E, Ubhi K, Phung V, MacLean-Lewis N, Askay D, Cartier A, Spencer B, Patrick C, Desplats P, Ellisman MH, Masliah E: Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity. PLoS One. 2010, 5: e14020-10.1371/journal.pone.0014020.PubMedCentralCrossRefPubMed Price DL, Rockenstein E, Ubhi K, Phung V, MacLean-Lewis N, Askay D, Cartier A, Spencer B, Patrick C, Desplats P, Ellisman MH, Masliah E: Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity. PLoS One. 2010, 5: e14020-10.1371/journal.pone.0014020.PubMedCentralCrossRefPubMed
20.
go back to reference Caraci F, Battaglia G, Sortino MA, Spampinato S, Molinaro G, Copani A, Nicoletti F, Bruno V: Metabotropic glutamate receptors in neurodegeneration/neuroprotection: still a hot topic?. Neurochem Int. 2012, 61: 559-565. 10.1016/j.neuint.2012.01.017.CrossRefPubMed Caraci F, Battaglia G, Sortino MA, Spampinato S, Molinaro G, Copani A, Nicoletti F, Bruno V: Metabotropic glutamate receptors in neurodegeneration/neuroprotection: still a hot topic?. Neurochem Int. 2012, 61: 559-565. 10.1016/j.neuint.2012.01.017.CrossRefPubMed
21.
go back to reference Lee HG, Zhu X, O’Neill MJ, Webber K, Casadesus G, Marlatt M, Raina AK, Perry G, Smith MA: The role of metabotropic glutamate receptors in Alzheimer’s disease. Acta Neurobiol Exp (Wars). 2004, 64: 89-98. Lee HG, Zhu X, O’Neill MJ, Webber K, Casadesus G, Marlatt M, Raina AK, Perry G, Smith MA: The role of metabotropic glutamate receptors in Alzheimer’s disease. Acta Neurobiol Exp (Wars). 2004, 64: 89-98.
22.
go back to reference Marino MJ, Valenti O, Conn PJ: Glutamate receptors and Parkinson’s disease: opportunities for intervention. Drugs Aging. 2003, 20: 377-397. 10.2165/00002512-200320050-00006.CrossRefPubMed Marino MJ, Valenti O, Conn PJ: Glutamate receptors and Parkinson’s disease: opportunities for intervention. Drugs Aging. 2003, 20: 377-397. 10.2165/00002512-200320050-00006.CrossRefPubMed
23.
go back to reference Feeley Kearney JA, Albin RL: mGluRs: a target for pharmacotherapy in Parkinson disease. Exp Neurol. 2003, 184 (Suppl 1): S30-S36.CrossRefPubMed Feeley Kearney JA, Albin RL: mGluRs: a target for pharmacotherapy in Parkinson disease. Exp Neurol. 2003, 184 (Suppl 1): S30-S36.CrossRefPubMed
24.
go back to reference Naie K, Manahan-Vaughan D: Regulation by metabotropic glutamate receptor 5 of LTP in the dentate gyrus of freely moving rats: relevance for learning and memory formation. Cereb Cortex. 2004, 14: 189-198. 10.1093/cercor/bhg118.CrossRefPubMed Naie K, Manahan-Vaughan D: Regulation by metabotropic glutamate receptor 5 of LTP in the dentate gyrus of freely moving rats: relevance for learning and memory formation. Cereb Cortex. 2004, 14: 189-198. 10.1093/cercor/bhg118.CrossRefPubMed
25.
go back to reference Simonyi A, Schachtman TR, Christoffersen GR: The role of metabotropic glutamate receptor 5 in learning and memory processes. Drug News Perspect. 2005, 18: 353-361. 10.1358/dnp.2005.18.6.927927.CrossRefPubMed Simonyi A, Schachtman TR, Christoffersen GR: The role of metabotropic glutamate receptor 5 in learning and memory processes. Drug News Perspect. 2005, 18: 353-361. 10.1358/dnp.2005.18.6.927927.CrossRefPubMed
26.
go back to reference Romano C, Sesma MA, McDonald CT, O’Malley K, Van den Pol AN, Olney JW: Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J Comp Neurol. 1995, 355: 455-469. 10.1002/cne.903550310.CrossRefPubMed Romano C, Sesma MA, McDonald CT, O’Malley K, Van den Pol AN, Olney JW: Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J Comp Neurol. 1995, 355: 455-469. 10.1002/cne.903550310.CrossRefPubMed
27.
go back to reference Marino MJ, Awad H, Poisik O, Wittmann M, Conn PJ: Localization and physiological roles of metabotropic glutamate receptors in the direct and indirect pathways of the basal ganglia. Amino Acids. 2002, 23: 185-191. 10.1007/s00726-001-0127-1.CrossRefPubMed Marino MJ, Awad H, Poisik O, Wittmann M, Conn PJ: Localization and physiological roles of metabotropic glutamate receptors in the direct and indirect pathways of the basal ganglia. Amino Acids. 2002, 23: 185-191. 10.1007/s00726-001-0127-1.CrossRefPubMed
28.
go back to reference Conn PJ, Battaglia G, Marino MJ, Nicoletti F: Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci. 2005, 6: 787-798. 10.1038/nrn1763.CrossRefPubMed Conn PJ, Battaglia G, Marino MJ, Nicoletti F: Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci. 2005, 6: 787-798. 10.1038/nrn1763.CrossRefPubMed
29.
go back to reference Albasanz JL, Dalfo E, Ferrer I, Martin M: Impaired metabotropic glutamate receptor/phospholipase C signaling pathway in the cerebral cortex in Alzheimer’s disease and dementia with Lewy bodies correlates with stage of Alzheimer’s-disease-related changes. Neurobiol Dis. 2005, 20: 685-693. 10.1016/j.nbd.2005.05.001.CrossRefPubMed Albasanz JL, Dalfo E, Ferrer I, Martin M: Impaired metabotropic glutamate receptor/phospholipase C signaling pathway in the cerebral cortex in Alzheimer’s disease and dementia with Lewy bodies correlates with stage of Alzheimer’s-disease-related changes. Neurobiol Dis. 2005, 20: 685-693. 10.1016/j.nbd.2005.05.001.CrossRefPubMed
30.
go back to reference Tyszkiewicz JP, Yan Z: beta-Amyloid peptides impair PKC-dependent functions of metabotropic glutamate receptors in prefrontal cortical neurons. J Neurophysiol. 2005, 93: 3102-3111. 10.1152/jn.00939.2004.CrossRefPubMed Tyszkiewicz JP, Yan Z: beta-Amyloid peptides impair PKC-dependent functions of metabotropic glutamate receptors in prefrontal cortical neurons. J Neurophysiol. 2005, 93: 3102-3111. 10.1152/jn.00939.2004.CrossRefPubMed
31.
go back to reference Oka A, Takashima S: The up-regulation of metabotropic glutamate receptor 5 (mGluR5) in Down’s syndrome brains. Acta Neuropathol (Berl). 1999, 97: 275-278. 10.1007/s004010050985.CrossRef Oka A, Takashima S: The up-regulation of metabotropic glutamate receptor 5 (mGluR5) in Down’s syndrome brains. Acta Neuropathol (Berl). 1999, 97: 275-278. 10.1007/s004010050985.CrossRef
32.
go back to reference Battaglia G, Busceti CL, Molinaro G, Biagioni F, Storto M, Fornai F, Nicoletti F, Bruno V: Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J Neurosci. 2004, 24: 828-835. 10.1523/JNEUROSCI.3831-03.2004.CrossRefPubMed Battaglia G, Busceti CL, Molinaro G, Biagioni F, Storto M, Fornai F, Nicoletti F, Bruno V: Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J Neurosci. 2004, 24: 828-835. 10.1523/JNEUROSCI.3831-03.2004.CrossRefPubMed
33.
go back to reference Flor PJ, Battaglia G, Nicoletti F, Gasparini F, Bruno V: Neuroprotective activity of metabotropic glutamate receptor ligands. Adv Exp Med Biol. 2002, 513: 197-223.CrossRefPubMed Flor PJ, Battaglia G, Nicoletti F, Gasparini F, Bruno V: Neuroprotective activity of metabotropic glutamate receptor ligands. Adv Exp Med Biol. 2002, 513: 197-223.CrossRefPubMed
34.
go back to reference Aguirre JA, Kehr J, Yoshitake T, Liu FL, Rivera A, Fernandez-Espinola S, Andbjer B, Leo G, Medhurst AD, Agnati LF, Fuxe K: Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP. Brain Res. 2005, 1033: 216-220. 10.1016/j.brainres.2004.11.040.CrossRefPubMed Aguirre JA, Kehr J, Yoshitake T, Liu FL, Rivera A, Fernandez-Espinola S, Andbjer B, Leo G, Medhurst AD, Agnati LF, Fuxe K: Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP. Brain Res. 2005, 1033: 216-220. 10.1016/j.brainres.2004.11.040.CrossRefPubMed
35.
go back to reference Vernon AC, Palmer S, Datla KP, Zbarsky V, Croucher MJ, Dexter DT: Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson’s disease. Eur J Neurosci. 2005, 22: 1799-1806. 10.1111/j.1460-9568.2005.04362.x.CrossRefPubMed Vernon AC, Palmer S, Datla KP, Zbarsky V, Croucher MJ, Dexter DT: Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson’s disease. Eur J Neurosci. 2005, 22: 1799-1806. 10.1111/j.1460-9568.2005.04362.x.CrossRefPubMed
36.
go back to reference Rockenstein E, Mallory M, Mante M, Sisk A, Masliaha E: Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1–42). J Neurosci Res. 2001, 66: 573-582. 10.1002/jnr.1247.CrossRefPubMed Rockenstein E, Mallory M, Mante M, Sisk A, Masliaha E: Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1–42). J Neurosci Res. 2001, 66: 573-582. 10.1002/jnr.1247.CrossRefPubMed
37.
go back to reference Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, Masliah E: Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res. 2002, 68: 568-578. 10.1002/jnr.10231.CrossRefPubMed Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, Masliah E: Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res. 2002, 68: 568-578. 10.1002/jnr.10231.CrossRefPubMed
38.
go back to reference Movsesyan VA, Stoica BA, Faden AI: MGLuR5 activation reduces beta-amyloid-induced cell death in primary neuronal cultures and attenuates translocation of cytochrome c and apoptosis-inducing factor. J Neurochem. 2004, 89: 1528-1536. 10.1111/j.1471-4159.2004.02451.x.CrossRefPubMed Movsesyan VA, Stoica BA, Faden AI: MGLuR5 activation reduces beta-amyloid-induced cell death in primary neuronal cultures and attenuates translocation of cytochrome c and apoptosis-inducing factor. J Neurochem. 2004, 89: 1528-1536. 10.1111/j.1471-4159.2004.02451.x.CrossRefPubMed
39.
go back to reference Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R: Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci. 2004, 24: 3370-3378. 10.1523/JNEUROSCI.1633-03.2004.CrossRefPubMed Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R: Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci. 2004, 24: 3370-3378. 10.1523/JNEUROSCI.1633-03.2004.CrossRefPubMed
40.
go back to reference Liu F, Gong X, Zhang G, Marquis K, Reinhart P, Andree TH: The inhibition of glycogen synthase kinase 3beta by a metabotropic glutamate receptor 5 mediated pathway confers neuroprotection to Abeta peptides. J Neurochem. 2005, 95: 1363-1372. 10.1111/j.1471-4159.2005.03474.x.CrossRefPubMed Liu F, Gong X, Zhang G, Marquis K, Reinhart P, Andree TH: The inhibition of glycogen synthase kinase 3beta by a metabotropic glutamate receptor 5 mediated pathway confers neuroprotection to Abeta peptides. J Neurochem. 2005, 95: 1363-1372. 10.1111/j.1471-4159.2005.03474.x.CrossRefPubMed
41.
go back to reference Blanchard BJ, Thomas VL, Ingram VM: Mechanism of membrane depolarization caused by the Alzheimer Abeta1-42 peptide. Biochem Biophys Res Commun. 2002, 293: 1197-1203. 10.1016/S0006-291X(02)00346-7.CrossRefPubMed Blanchard BJ, Thomas VL, Ingram VM: Mechanism of membrane depolarization caused by the Alzheimer Abeta1-42 peptide. Biochem Biophys Res Commun. 2002, 293: 1197-1203. 10.1016/S0006-291X(02)00346-7.CrossRefPubMed
42.
go back to reference Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, Klein WL, Triller A: Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron. 2010, 66: 739-754. 10.1016/j.neuron.2010.04.029.PubMedCentralCrossRefPubMed Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, Klein WL, Triller A: Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron. 2010, 66: 739-754. 10.1016/j.neuron.2010.04.029.PubMedCentralCrossRefPubMed
43.
go back to reference Lea PM, Movsesyan VA, Faden AI: Neuroprotective activity of the mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not reflect actions at mGluR5 receptors. Br J Pharmacol. 2005, 145: 527-534.PubMedCentralCrossRefPubMed Lea PM, Movsesyan VA, Faden AI: Neuroprotective activity of the mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not reflect actions at mGluR5 receptors. Br J Pharmacol. 2005, 145: 527-534.PubMedCentralCrossRefPubMed
44.
go back to reference Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, Kretzschmar H, Hengerer B, Kostka M: Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci. 2007, 27: 9220-9232. 10.1523/JNEUROSCI.2617-07.2007.CrossRefPubMed Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, Kretzschmar H, Hengerer B, Kostka M: Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci. 2007, 27: 9220-9232. 10.1523/JNEUROSCI.2617-07.2007.CrossRefPubMed
45.
go back to reference Arispe N, Rojas E, Pollard HB: Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci U S A. 1993, 90: 567-571. 10.1073/pnas.90.2.567.PubMedCentralCrossRefPubMed Arispe N, Rojas E, Pollard HB: Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci U S A. 1993, 90: 567-571. 10.1073/pnas.90.2.567.PubMedCentralCrossRefPubMed
46.
go back to reference Kawahara M, Negishi-Kato M, Sadakane Y: Calcium dyshomeostasis and neurotoxicity of Alzheimer’s beta-amyloid protein. Expert Rev Neurother. 2009, 9: 681-693. 10.1586/ern.09.28.CrossRefPubMed Kawahara M, Negishi-Kato M, Sadakane Y: Calcium dyshomeostasis and neurotoxicity of Alzheimer’s beta-amyloid protein. Expert Rev Neurother. 2009, 9: 681-693. 10.1586/ern.09.28.CrossRefPubMed
47.
go back to reference Dufty BM, Warner LR, Hou ST, Jiang SX, Gomez-Isla T, Leenhouts KM, Oxford JT, Feany MB, Masliah E, Rohn TT: Calpain-cleavage of {alpha}-synuclein: connecting proteolytic processing to disease-linked aggregation. Am J Pathol. 2007, 170: 1725-1738. 10.2353/ajpath.2007.061232.PubMedCentralCrossRefPubMed Dufty BM, Warner LR, Hou ST, Jiang SX, Gomez-Isla T, Leenhouts KM, Oxford JT, Feany MB, Masliah E, Rohn TT: Calpain-cleavage of {alpha}-synuclein: connecting proteolytic processing to disease-linked aggregation. Am J Pathol. 2007, 170: 1725-1738. 10.2353/ajpath.2007.061232.PubMedCentralCrossRefPubMed
48.
go back to reference Mishizen-Eberz AJ, Guttmann RP, Giasson BI, Day GA, Hodara R, Ischiropoulos H, Lee VM, Trojanowski JQ, Lynch DR: Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. J Neurochem. 2003, 86: 836-847. 10.1046/j.1471-4159.2003.01878.x.CrossRefPubMed Mishizen-Eberz AJ, Guttmann RP, Giasson BI, Day GA, Hodara R, Ischiropoulos H, Lee VM, Trojanowski JQ, Lynch DR: Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. J Neurochem. 2003, 86: 836-847. 10.1046/j.1471-4159.2003.01878.x.CrossRefPubMed
49.
go back to reference Mishizen-Eberz AJ, Norris EH, Giasson BI, Hodara R, Ischiropoulos H, Lee VM, Trojanowski JQ, Lynch DR: Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. Biochemistry. 2005, 44: 7818-7829. 10.1021/bi047846q.CrossRefPubMed Mishizen-Eberz AJ, Norris EH, Giasson BI, Hodara R, Ischiropoulos H, Lee VM, Trojanowski JQ, Lynch DR: Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. Biochemistry. 2005, 44: 7818-7829. 10.1021/bi047846q.CrossRefPubMed
50.
go back to reference Kim SJ, Sung JY, Um JW, Hattori N, Mizuno Y, Tanaka K, Paik SR, Kim J, Chung KC: Parkin cleaves intracellular alpha-synuclein inclusions via the activation of calpain. J Biol Chem. 2003, 278: 41890-41899. 10.1074/jbc.M306017200.CrossRefPubMed Kim SJ, Sung JY, Um JW, Hattori N, Mizuno Y, Tanaka K, Paik SR, Kim J, Chung KC: Parkin cleaves intracellular alpha-synuclein inclusions via the activation of calpain. J Biol Chem. 2003, 278: 41890-41899. 10.1074/jbc.M306017200.CrossRefPubMed
51.
go back to reference Games D, Seubert P, Rockenstein E, Patrick C, Trejo M, Ubhi K, Ettle B, Ghassemiam M, Barbour R, Schenk D, Nuber S, Masliah E: Axonopathy in an alpha-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated alpha-synuclein. Am J Pathol. 2013, 182: 940-953. 10.1016/j.ajpath.2012.11.018.PubMedCentralCrossRefPubMed Games D, Seubert P, Rockenstein E, Patrick C, Trejo M, Ubhi K, Ettle B, Ghassemiam M, Barbour R, Schenk D, Nuber S, Masliah E: Axonopathy in an alpha-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated alpha-synuclein. Am J Pathol. 2013, 182: 940-953. 10.1016/j.ajpath.2012.11.018.PubMedCentralCrossRefPubMed
52.
go back to reference Luk KC, Kehm VM, Zhang B, O’Brien P, Trojanowski JQ, Lee VM: Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med. 2012, 209: 975-986. 10.1084/jem.20112457.PubMedCentralCrossRefPubMed Luk KC, Kehm VM, Zhang B, O’Brien P, Trojanowski JQ, Lee VM: Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med. 2012, 209: 975-986. 10.1084/jem.20112457.PubMedCentralCrossRefPubMed
53.
go back to reference Tofaris GK, Garcia Reitbock P, Humby T, Lambourne SL, O’Connell M, Ghetti B, Gossage H, Emson PC, Wilkinson LS, Goedert M, Spillantini MG: Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1–120): implications for Lewy body disorders. J Neurosci. 2006, 26: 3942-3950. 10.1523/JNEUROSCI.4965-05.2006.CrossRefPubMed Tofaris GK, Garcia Reitbock P, Humby T, Lambourne SL, O’Connell M, Ghetti B, Gossage H, Emson PC, Wilkinson LS, Goedert M, Spillantini MG: Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1–120): implications for Lewy body disorders. J Neurosci. 2006, 26: 3942-3950. 10.1523/JNEUROSCI.4965-05.2006.CrossRefPubMed
54.
go back to reference Ulusoy A, Febbraro F, Jensen PH, Kirik D, Romero-Ramos M: Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology. Eur J Neurosci. 2010, 32: 409-422. 10.1111/j.1460-9568.2010.07284.x.CrossRefPubMed Ulusoy A, Febbraro F, Jensen PH, Kirik D, Romero-Ramos M: Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology. Eur J Neurosci. 2010, 32: 409-422. 10.1111/j.1460-9568.2010.07284.x.CrossRefPubMed
55.
go back to reference Daher JP, Ying M, Banerjee R, McDonald RS, Hahn MD, Yang L, Flint Beal M, Thomas B, Dawson VL, Dawson TM, Moore DJ: Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons. Mol Neurodegener. 2009, 4: 34-10.1186/1750-1326-4-34.PubMedCentralCrossRefPubMed Daher JP, Ying M, Banerjee R, McDonald RS, Hahn MD, Yang L, Flint Beal M, Thomas B, Dawson VL, Dawson TM, Moore DJ: Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons. Mol Neurodegener. 2009, 4: 34-10.1186/1750-1326-4-34.PubMedCentralCrossRefPubMed
56.
go back to reference Nuber S, Harmuth F, Kohl Z, Adame A, Trejo M, Schonig K, Zimmermann F, Bauer C, Casadei N, Giel C, Calaminus C, Pichler BJ, Jensen PH, Muller CP, Amato D, Kornhuber J, Teismann P, Yamakado H, Takahashi R, Winkler J, Masliah E, Riess O: A progressive dopaminergic phenotype associated with neurotoxic conversion of alpha-synuclein in BAC-transgenic rats. Brain. 2013, 136: 412-432. 10.1093/brain/aws358.PubMedCentralCrossRefPubMed Nuber S, Harmuth F, Kohl Z, Adame A, Trejo M, Schonig K, Zimmermann F, Bauer C, Casadei N, Giel C, Calaminus C, Pichler BJ, Jensen PH, Muller CP, Amato D, Kornhuber J, Teismann P, Yamakado H, Takahashi R, Winkler J, Masliah E, Riess O: A progressive dopaminergic phenotype associated with neurotoxic conversion of alpha-synuclein in BAC-transgenic rats. Brain. 2013, 136: 412-432. 10.1093/brain/aws358.PubMedCentralCrossRefPubMed
57.
go back to reference Grolla AA, Sim JA, Lim D, Rodriguez JJ, Genazzani AA, Verkhratsky A: Amyloid-beta and Alzheimer’s disease type pathology differentially affects the calcium signalling toolkit in astrocytes from different brain regions. Cell Death Dis. 2013, 4: e623-10.1038/cddis.2013.145.PubMedCentralCrossRefPubMed Grolla AA, Sim JA, Lim D, Rodriguez JJ, Genazzani AA, Verkhratsky A: Amyloid-beta and Alzheimer’s disease type pathology differentially affects the calcium signalling toolkit in astrocytes from different brain regions. Cell Death Dis. 2013, 4: e623-10.1038/cddis.2013.145.PubMedCentralCrossRefPubMed
58.
go back to reference Cleva RM, Olive MF: Positive allosteric modulators of type 5 metabotropic glutamate receptors (mGluR5) and their therapeutic potential for the treatment of CNS disorders. Molecules. 2011, 16: 2097-2106. 10.3390/molecules16032097.PubMedCentralCrossRefPubMed Cleva RM, Olive MF: Positive allosteric modulators of type 5 metabotropic glutamate receptors (mGluR5) and their therapeutic potential for the treatment of CNS disorders. Molecules. 2011, 16: 2097-2106. 10.3390/molecules16032097.PubMedCentralCrossRefPubMed
59.
go back to reference Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, Takahashi H, Kerrisk ME, Vortmeyer A, Wisniewski T, Koleske AJ, Gunther EC, Nygaard HB, Strittmatter SM: Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein. Neuron. 2013, 79: 887-902. 10.1016/j.neuron.2013.06.036.PubMedCentralCrossRefPubMed Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, Takahashi H, Kerrisk ME, Vortmeyer A, Wisniewski T, Koleske AJ, Gunther EC, Nygaard HB, Strittmatter SM: Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein. Neuron. 2013, 79: 887-902. 10.1016/j.neuron.2013.06.036.PubMedCentralCrossRefPubMed
60.
go back to reference Lim D, Iyer A, Ronco V, Grolla AA, Canonico PL, Aronica E, Genazzani AA: Amyloid beta deregulates astroglial mGluR5-mediated calcium signaling via calcineurin and Nf-kB. Glia. 2013, 61: 1134-1145. 10.1002/glia.22502.CrossRefPubMed Lim D, Iyer A, Ronco V, Grolla AA, Canonico PL, Aronica E, Genazzani AA: Amyloid beta deregulates astroglial mGluR5-mediated calcium signaling via calcineurin and Nf-kB. Glia. 2013, 61: 1134-1145. 10.1002/glia.22502.CrossRefPubMed
61.
go back to reference Hsieh MH, Ho SC, Yeh KY, Pawlak CR, Chang HM, Ho YJ, Lai TJ, Wu FY: Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson’s disease rat model. Pharmacol Biochem Behav. 2012, 102: 64-71. 10.1016/j.pbb.2012.03.022.CrossRefPubMed Hsieh MH, Ho SC, Yeh KY, Pawlak CR, Chang HM, Ho YJ, Lai TJ, Wu FY: Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson’s disease rat model. Pharmacol Biochem Behav. 2012, 102: 64-71. 10.1016/j.pbb.2012.03.022.CrossRefPubMed
62.
go back to reference Black YD, Xiao D, Pellegrino D, Kachroo A, Brownell AL, Schwarzschild MA: Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson’s disease. Neurosci Lett. 2010, 486: 161-165. 10.1016/j.neulet.2010.09.043.PubMedCentralCrossRefPubMed Black YD, Xiao D, Pellegrino D, Kachroo A, Brownell AL, Schwarzschild MA: Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson’s disease. Neurosci Lett. 2010, 486: 161-165. 10.1016/j.neulet.2010.09.043.PubMedCentralCrossRefPubMed
63.
go back to reference Marsh SE, Blurton-Jones M: Examining the mechanisms that link beta-amyloid and alpha-synuclein pathologies. Alzheimers Res Ther. 2012, 4: 11-10.1186/alzrt109.PubMedCentralCrossRefPubMed Marsh SE, Blurton-Jones M: Examining the mechanisms that link beta-amyloid and alpha-synuclein pathologies. Alzheimers Res Ther. 2012, 4: 11-10.1186/alzrt109.PubMedCentralCrossRefPubMed
64.
go back to reference Bate C, Gentleman S, Williams A: alpha-synuclein induced synapse damage is enhanced by amyloid-beta1-42. Mol Neurodegener. 2010, 5: 55-10.1186/1750-1326-5-55.PubMedCentralCrossRefPubMed Bate C, Gentleman S, Williams A: alpha-synuclein induced synapse damage is enhanced by amyloid-beta1-42. Mol Neurodegener. 2010, 5: 55-10.1186/1750-1326-5-55.PubMedCentralCrossRefPubMed
65.
go back to reference Ono K, Takahashi R, Ikeda T, Yamada M: Cross-seeding effects of amyloid beta-protein and alpha-synuclein. J Neurochem. 2012, 122: 883-890. 10.1111/j.1471-4159.2012.07847.x.CrossRefPubMed Ono K, Takahashi R, Ikeda T, Yamada M: Cross-seeding effects of amyloid beta-protein and alpha-synuclein. J Neurochem. 2012, 122: 883-890. 10.1111/j.1471-4159.2012.07847.x.CrossRefPubMed
66.
go back to reference Henning Jensen P: α-Synuclein/Amyloid Interactions. Methods Mol Med. 2001, 62: 61-65.PubMed Henning Jensen P: α-Synuclein/Amyloid Interactions. Methods Mol Med. 2001, 62: 61-65.PubMed
67.
go back to reference Bar-On P, Crews L, Koob AO, Mizuno H, Adame A, Spencer B, Masliah E: Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson’s disease. J Neurochem. 2008, 105: 1656-1667. 10.1111/j.1471-4159.2008.05254.x.PubMedCentralCrossRefPubMed Bar-On P, Crews L, Koob AO, Mizuno H, Adame A, Spencer B, Masliah E: Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson’s disease. J Neurochem. 2008, 105: 1656-1667. 10.1111/j.1471-4159.2008.05254.x.PubMedCentralCrossRefPubMed
68.
go back to reference Tiscornia G, Singer O, Verma IM: Design and cloning of lentiviral vectors expressing small interfering RNAs. Nat Protoc. 2006, 1: 234-240. 10.1038/nprot.2006.36.CrossRefPubMed Tiscornia G, Singer O, Verma IM: Design and cloning of lentiviral vectors expressing small interfering RNAs. Nat Protoc. 2006, 1: 234-240. 10.1038/nprot.2006.36.CrossRefPubMed
69.
go back to reference Spencer B, Potkar R, Trejo M, Rockenstein E, Patrick C, Gindi R, Adame A, Wyss-Coray T, Masliah E: Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson’s and Lewy body diseases. J Neurosci. 2009, 29: 13578-13588. 10.1523/JNEUROSCI.4390-09.2009.PubMedCentralCrossRefPubMed Spencer B, Potkar R, Trejo M, Rockenstein E, Patrick C, Gindi R, Adame A, Wyss-Coray T, Masliah E: Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson’s and Lewy body diseases. J Neurosci. 2009, 29: 13578-13588. 10.1523/JNEUROSCI.4390-09.2009.PubMedCentralCrossRefPubMed
70.
go back to reference Marr RA, Rockenstein E, Mukherjee A, Kindy MS, Hersh LB, Gage FH, Verma IM, Masliah E: Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci. 2003, 23: 1992-1996.PubMed Marr RA, Rockenstein E, Mukherjee A, Kindy MS, Hersh LB, Gage FH, Verma IM, Masliah E: Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci. 2003, 23: 1992-1996.PubMed
71.
go back to reference Franklin KBJ, Paxinos G: The mouse brain in stereotaxic coordinates. 1997, San Diego: Academic Press Franklin KBJ, Paxinos G: The mouse brain in stereotaxic coordinates. 1997, San Diego: Academic Press
72.
go back to reference Zwilling D, Huang SY, Sathyasaikumar KV, Notarangelo FM, Guidetti P, Wu HQ, Lee J, Truong J, Andrews-Zwilling Y, Hsieh EW, Louie JY, Wu T, Scearce-Levie K, Patrick C, Adame A, Giorgini F, Moussaoui S, Laue G, Rassoulpour A, Flik G, Huang Y, Muchowski JM, Masliah E, Schwarcz R, Muchowski PJ: Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell. 2011, 145: 863-874. 10.1016/j.cell.2011.05.020.PubMedCentralCrossRefPubMed Zwilling D, Huang SY, Sathyasaikumar KV, Notarangelo FM, Guidetti P, Wu HQ, Lee J, Truong J, Andrews-Zwilling Y, Hsieh EW, Louie JY, Wu T, Scearce-Levie K, Patrick C, Adame A, Giorgini F, Moussaoui S, Laue G, Rassoulpour A, Flik G, Huang Y, Muchowski JM, Masliah E, Schwarcz R, Muchowski PJ: Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell. 2011, 145: 863-874. 10.1016/j.cell.2011.05.020.PubMedCentralCrossRefPubMed
73.
go back to reference Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L: Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 2000, 287: 1265-1269. 10.1126/science.287.5456.1265.CrossRefPubMed Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L: Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 2000, 287: 1265-1269. 10.1126/science.287.5456.1265.CrossRefPubMed
74.
go back to reference Overk CR, Kelley CM, Mufson EJ: Brainstem Alzheimer’s-like pathology in the triple transgenic mouse model of Alzheimer’s disease. Neurobiol Dis. 2009, 35: 415-425. 10.1016/j.nbd.2009.06.004.PubMedCentralCrossRefPubMed Overk CR, Kelley CM, Mufson EJ: Brainstem Alzheimer’s-like pathology in the triple transgenic mouse model of Alzheimer’s disease. Neurobiol Dis. 2009, 35: 415-425. 10.1016/j.nbd.2009.06.004.PubMedCentralCrossRefPubMed
75.
go back to reference Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, Mueller-Steiner S, Seubert P, Barbour R, McConlogue L, Buttini M, Games D, Schenk D: Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One. 2011, 6: e19338-10.1371/journal.pone.0019338.PubMedCentralCrossRefPubMed Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, Mueller-Steiner S, Seubert P, Barbour R, McConlogue L, Buttini M, Games D, Schenk D: Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One. 2011, 6: e19338-10.1371/journal.pone.0019338.PubMedCentralCrossRefPubMed
76.
go back to reference Pham E, Crews L, Ubhi K, Hansen L, Adame A, Cartier A, Salmon D, Galasko D, Michael S, Savas JN, Yates JR, Glabe C, Masliah E: Progressive accumulation of amyloid-beta oligomers in Alzheimer’s disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. FEBS J. 2010, 277: 3051-3067.PubMedCentralCrossRefPubMed Pham E, Crews L, Ubhi K, Hansen L, Adame A, Cartier A, Salmon D, Galasko D, Michael S, Savas JN, Yates JR, Glabe C, Masliah E: Progressive accumulation of amyloid-beta oligomers in Alzheimer’s disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. FEBS J. 2010, 277: 3051-3067.PubMedCentralCrossRefPubMed
77.
go back to reference Hashimoto M, Rockenstein E, Mante M, Mallory M, Masliah E: b-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron. 2001, 32: 213-223. 10.1016/S0896-6273(01)00462-7.CrossRefPubMed Hashimoto M, Rockenstein E, Mante M, Mallory M, Masliah E: b-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron. 2001, 32: 213-223. 10.1016/S0896-6273(01)00462-7.CrossRefPubMed
78.
go back to reference Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ: Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002, 416: 535-539. 10.1038/416535a.CrossRefPubMed Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ: Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002, 416: 535-539. 10.1038/416535a.CrossRefPubMed
79.
go back to reference Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, Murphy MP, Golde TE: Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest. 2006, 116: 193-201.PubMedCentralCrossRefPubMed Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, Murphy MP, Golde TE: Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest. 2006, 116: 193-201.PubMedCentralCrossRefPubMed
Metadata
Title
Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5 – implications for dementia with Lewy bodies
Authors
Cassia R Overk
Anna Cartier
Gideon Shaked
Edward Rockenstein
Kiren Ubhi
Brian Spencer
Diana L Price
Christina Patrick
Paula Desplats
Eliezer Masliah
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Molecular Neurodegeneration / Issue 1/2014
Electronic ISSN: 1750-1326
DOI
https://doi.org/10.1186/1750-1326-9-18

Other articles of this Issue 1/2014

Molecular Neurodegeneration 1/2014 Go to the issue